ReNeuron Group plc - ReNeuron's lead cell line shows further potential
ReNeuron Group plc
New data show
re-programmed into a pluripotent state and differentiated into other cell types
These new cell types can be efficiently expanded as potential cell therapy candidates targeting a broad range of diseases
The Company has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can be successfully and rapidly re-programmed to an embryonic stem cell-like state enabling differentiation into any cell type. In essence, this means that the Company is able to take its neural stem cells back to being stem cells that can be made to develop into any other type of stem cell including bone, nerve, muscle and skin.
The new data being presented today show for the first time that these CTX-iPSCs (induced pluripotent stem cells) can indeed be differentiated along different cell lineages to generate, for example, mesenchymal stem cell lines. Further, the mesenchymal stem cell lines generated can be grown at scale by virtue of the Company's conditional immortalisation technology, enabling the efficient production of clinical-grade cell therapy candidates.
These results are particularly encouraging as they demonstrate that CTX, a well-characterised, clinical-grade neural stem cell line, could be used to produce new conditionally immortalised allogeneic (i.e. non-donor-specific) cell lines from any of the three primary germ cell layers which form during embryonic development.
Further information about the conference may be found at:
Commenting on the data, Dr
"The data we are presenting at the ESGCT Annual Congress represent a significant advance in the use of cell re-programming to generate new allogeneic cell lines as potential therapeutic candidates. Importantly, the maintenance of the immortalisation technology within these new cell lines may allow for the scaled production of 'off the shelf' allogeneic stem cells, such as haematopoietic stem cells as a potential alternative approach to those cancer immunotherapies currently in development that rely on the use of the patient's own T-cells."
| || |
+44 (0)20 3819 8400
| || |
| || |
+44 (0) 20 7466 5000
+1 212 600 1902
+44 (0) 20 7710 7600
| || |
+44 (0) 20 7496 3000
This information is provided by RNS, the news service of the
Quick facts: ReNeuron Group PLC
Market Cap: £34.7 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE